No Data
No Data
No Data
No Data
No Data
Forte Biosciences Raised to Buy From Neutral by Ladenburg Thalmann
Forte Biosciences Raised to Buy From Neutral by Ladenburg Thalmann
Dow JonesApr 8 17:46 ET
Ladenburg Thalmann Upgrades Forte Biosciences to Buy, Announces $2.75 Price Target
Ladenburg Thalmann analyst Michael Higgins upgrades Forte Biosciences (NASDAQ:FBRX) from Neutral to Buy and announces $2.75 price target.
BenzingaApr 8 17:36 ET
Forte Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/08/2024 292.3% Ladenburg Thalmann → $2.75 Upgrades Neutral → Buy 09/20/2021 399.29% Chardan Capital $4
BenzingaApr 8 17:35 ET
Buy Recommendation for Forte Biosciences on Strong Potential of Novel FB-102 Treatment and Market Position
TipRanksApr 8 06:45 ET
Forte Biosciences GAAP EPS of -$1.00
Seeking AlphaMar 18 16:42 ET
Forte Biosciences, Inc. Announces 2023 EPS $(1.00) Vs $(0.80) YoY
2023 Operating ResultsResearch and development expenses were $21.9 million for the year ended December 31, 2023, compared to $5.6 million during the same period in 2022. The increase of $16.3 million
BenzingaMar 18 16:13 ET
THE_MrCheeseOmelette : Could have pumped hard but a lot of big players offloaded it looks like
Lucky2828 THE_MrCheeseOmelette: This is basically short sale. They sold high and cover low. The volume looks good in post market. I think they will cover their position before the market close at 8am. Don't worry, once u brought, be confident.
No Data
No Data